THTX Valuation

Theratechnologies Inc

Add to Watchlist

Advanced Chart

3.180

+0.02(0.633%)1D

Overview
Forecast
Valuation
Earnings

THTX Relative Valuation

THTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, THTX is overvalued; if below, it's undervalued.

Historical Valuation

Theratechnologies Inc (THTX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.73 is considered Fairly compared with the five-year average of 7.43. The fair price of Theratechnologies Inc (THTX) is between 1.83 to 5.35 according to relative valuation methord.

Relative Value

Fair Zone

1.83-5.35

Current Price：3.18

Fair

79.16

Trailing

Forward

9.34

EV/EBITDA

Theratechnologies Inc. (THTX) has a current EV/EBITDA of 9.34. The 5-year average EV/EBITDA is 77.79. The thresholds are as follows: Strongly Undervalued below -632.19, Undervalued between -632.19 and -277.20, Fairly Valued between 432.78 and -277.20, Overvalued between 432.78 and 787.76, and Strongly Overvalued above 787.76. The current Forward EV/EBITDA of 9.34 falls within the Historic Trend Line -Fairly Valued range.

28.94

EV/EBIT

Theratechnologies Inc. (THTX) has a current EV/EBIT of 28.94. The 5-year average EV/EBIT is -6.17. The thresholds are as follows: Strongly Undervalued below -30.26, Undervalued between -30.26 and -18.22, Fairly Valued between 5.87 and -18.22, Overvalued between 5.87 and 17.92, and Strongly Overvalued above 17.92. The current Forward EV/EBIT of 28.94 falls within the Strongly Overvalued range.

1.73

Theratechnologies Inc. (THTX) has a current PS of 1.73. The 5-year average PS is 1.88. The thresholds are as follows: Strongly Undervalued below -0.50, Undervalued between -0.50 and 0.69, Fairly Valued between 3.07 and 0.69, Overvalued between 3.07 and 4.27, and Strongly Overvalued above 4.27. The current Forward PS of 1.73 falls within the Historic Trend Line -Fairly Valued range.

34.42

P/OCF

Theratechnologies Inc. (THTX) has a current P/OCF of 34.42. The 5-year average P/OCF is -1.33. The thresholds are as follows: Strongly Undervalued below -40.53, Undervalued between -40.53 and -20.93, Fairly Valued between 18.28 and -20.93, Overvalued between 18.28 and 37.88, and Strongly Overvalued above 37.88. The current Forward P/OCF of 34.42 falls within the Overvalued range.

18.57

P/FCF

Theratechnologies Inc. (THTX) has a current P/FCF of 18.57. The 5-year average P/FCF is 0.28. The thresholds are as follows: Strongly Undervalued below -60.24, Undervalued between -60.24 and -29.98, Fairly Valued between 30.54 and -29.98, Overvalued between 30.54 and 60.80, and Strongly Overvalued above 60.80. The current Forward P/FCF of 18.57 falls within the Historic Trend Line -Fairly Valued range.

Theratechnologies Inc (THTX) has a current Price-to-Book (P/B) ratio of -5.20. Compared to its 3-year average P/B ratio of -4.02 , the current P/B ratio is approximately 29.51% higher. Relative to its 5-year average P/B ratio of 4.58, the current P/B ratio is about -213.50% higher. Theratechnologies Inc (THTX) has a Forward Free Cash Flow (FCF) yield of approximately 4.85%. Compared to its 3-year average FCF yield of -9.22%, the current FCF yield is approximately -152.64% lower. Relative to its 5-year average FCF yield of -7.79% , the current FCF yield is about -162.30% lower.

-5.20

P/B

Median3y

-4.02

Median5y

4.58

4.85

FCF Yield

Median3y

-9.22

Median5y

-7.79

Competitors Valuation Multiple

The average P/S ratio for THTX's competitors is 1.93, providing a benchmark for relative valuation. Theratechnologies Inc Corp (THTX) exhibits a P/S ratio of 1.73, which is -10.42% above the industry average. Given its robust revenue growth of -19.48%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

THTX.O

Theratechnologies Inc

China SXT Pharmaceuticals Inc

Loss

174.04M

ELDN.O

Eledon Pharmaceuticals Inc

Loss

205.99M

YMAB.O

Y-mAbs Therapeutics Inc

Performance Decomposition

Market capitalization of THTX increased by 148.44% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.81 to -16.79.

The secondary factor is the Revenue Growth, contributed -19.48%to the performance.

Overall, the performance of THTX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-19.48%

22.02M → 17.73M

Revenue Growth

-661.83%

4.48 → -25.17

Margin Expansion

829.75%

-1.81 → -16.79

P/E Change

148.44%